Apellis Pharmaceuticals Inc (APLS)
27.98
+0.72
(+2.64%)
USD |
NASDAQ |
Nov 01, 16:00
27.97
-0.01
(-0.04%)
After-Hours: 20:00
Apellis Pharmaceuticals Net Income (Quarterly): -37.66M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -37.66M |
March 31, 2024 | -66.42M |
December 31, 2023 | -88.58M |
September 30, 2023 | -140.24M |
June 30, 2023 | -122.04M |
March 31, 2023 | -177.78M |
December 31, 2022 | -165.99M |
September 30, 2022 | -191.27M |
June 30, 2022 | -155.98M |
March 31, 2022 | -138.94M |
December 31, 2021 | -147.93M |
September 30, 2021 | -195.57M |
June 30, 2021 | -219.19M |
March 31, 2021 | -183.66M |
December 31, 2020 | 78.26M |
September 30, 2020 | -135.70M |
June 30, 2020 | -118.62M |
March 31, 2020 | -168.82M |
Date | Value |
---|---|
December 31, 2019 | -113.22M |
September 30, 2019 | -69.82M |
June 30, 2019 | -71.09M |
March 31, 2019 | -50.57M |
December 31, 2018 | -36.89M |
September 30, 2018 | -35.55M |
June 30, 2018 | -33.33M |
March 31, 2018 | -21.74M |
December 31, 2017 | -18.26M |
September 30, 2017 | -11.57M |
June 30, 2017 | -12.13M |
March 31, 2017 | -9.051M |
December 31, 2016 | -6.620M |
September 30, 2016 | -7.211M |
December 31, 2015 | -8.216M |
September 30, 2015 | -31.19M |
December 31, 2014 | -2.689M |
September 30, 2014 | -2.47M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-219.19M
Minimum
Jun 2021
78.26M
Maximum
Dec 2020
-131.02M
Average
-140.24M
Median
Sep 2023
Net Income (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 106.08M |
Ionis Pharmaceuticals Inc | -66.26M |
EyePoint Pharmaceuticals Inc | -30.83M |
Cassava Sciences Inc | 6.155M |
Macrogenics Inc | -55.66M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 199.68M |
Total Expenses (Quarterly) | 229.13M |
EPS Diluted (Quarterly) | -0.30 |
Enterprise Value | 3.504B |
Gross Profit Margin (Quarterly) | 88.43% |
Profit Margin (Quarterly) | -18.86% |
Earnings Yield | -9.79% |
Normalized Earnings Yield | -9.748 |